These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 18454047)

  • 1. The novel platinum(IV) complex LA-12 induces p53 and p53/47 responses that differ from the related drug, cisplatin.
    Hrstka R; Powell DJ; Kvardova V; Roubalova E; Bourougaa K; Candeias MM; Sova P; Zak F; Fåhraeus R; Vojtĕsek B
    Anticancer Drugs; 2008 Apr; 19(4):369-79. PubMed ID: 18454047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High effectiveness of platinum(IV) complex with adamantylamine in overcoming resistance to cisplatin and suppressing proliferation of ovarian cancer cells in vitro.
    Kozubík A; Horváth V; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Zák F; Mistr A; Turánek J
    Biochem Pharmacol; 2005 Feb; 69(3):373-83. PubMed ID: 15652229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells.
    Horváth V; Blanárová O; Svihálková-Sindlerová L; Soucek K; Hofmanová J; Sova P; Kroutil A; Fedorocko P; Kozubík A
    Gynecol Oncol; 2006 Jul; 102(1):32-40. PubMed ID: 16364413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
    Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
    Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptosis and inhibition of gap-junctional intercellular communication induced by LA-12, a novel hydrophobic platinum(IV) complex.
    Procházka L; Turánek J; Tesarík R; Knotigová P; Polásková P; Andrysík Z; Kozubík A; Zák F; Sova P; Neuzil J; Machala M
    Arch Biochem Biophys; 2007 Jun; 462(1):54-61. PubMed ID: 17466256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platinum(IV) complex with adamantylamine as nonleaving amine group: synthesis, characterization, and in vitro antitumor activity against a panel of cisplatin-resistant cancer cell lines.
    Zák F; Turánek J; Kroutil A; Sova P; Mistr A; Poulová A; Mikolin P; Zák Z; Kasná A; Záluská D; Neca J; Sindlerová L; Kozubík A
    J Med Chem; 2004 Jan; 47(3):761-3. PubMed ID: 14736257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
    Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
    Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
    Stordal BK; Davey MW; Davey RA
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LA-12 overcomes confluence-dependent resistance of HT-29 colon cancer cells to Pt (II) compounds.
    Svihálková-Sindlerová L; Foltinová V; Vaculová A; Horváth V; Soucek K; Sova P; Hofmanová J; Kozubík A
    Anticancer Res; 2010 Apr; 30(4):1183-8. PubMed ID: 20530425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses.
    Konstantakou EG; Voutsinas GE; Karkoulis PK; Aravantinos G; Margaritis LH; Stravopodis DJ
    Int J Oncol; 2009 Aug; 35(2):401-16. PubMed ID: 19578756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different cell cycle modulation following treatment of human ovarian carcinoma cells with a new platinum(IV) complex vs cisplatin.
    Horváth V; Soucek K; Svihálková-Sindlerová L; Vondrácek J; Blanárová O; Hofmanová J; Sova P; Kozubík A
    Invest New Drugs; 2007 Oct; 25(5):435-43. PubMed ID: 17520175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin.
    Avery-Kiejda KA; Zhang XD; Adams LJ; Scott RJ; Vojtesek B; Lane DP; Hersey P
    Clin Cancer Res; 2008 Mar; 14(6):1659-68. PubMed ID: 18310316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents.
    Hamberger J; Liebeke M; Kaiser M; Bracht K; Olszewski U; Zeillinger R; Hamilton G; Braun D; Bednarski PJ
    Anticancer Drugs; 2009 Aug; 20(7):559-72. PubMed ID: 19491657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
    Yanagie H; Hisa T; Ogata A; Miyazaki A; Nonaka Y; Nishihira T; Osada I; Sairennji T; Sugiyama H; Furuya Y; Kidani Y; Takamoto S; Takahashi H; Eriguchi M
    Biomed Pharmacother; 2009 Sep; 63(8):553-60. PubMed ID: 18571892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The involvement of XPC protein in the cisplatin DNA damaging treatment-mediated cellular response.
    Wang G; Dombkowski A; Chuang L; Xu XX
    Cell Res; 2004 Aug; 14(4):303-14. PubMed ID: 15353127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.
    Kelland LR; Sharp SY; O'Neill CF; Raynaud FI; Beale PJ; Judson IR
    J Inorg Biochem; 1999 Oct; 77(1-2):111-5. PubMed ID: 10626362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
    Martelli L; Di Mario F; Botti P; Ragazzi E; Martelli M; Kelland L
    Biochem Pharmacol; 2007 Jun; 74(1):20-7. PubMed ID: 17466278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin.
    Kvardova V; Hrstka R; Walerych D; Muller P; Matoulkova E; Hruskova V; Stelclova D; Sova P; Vojtesek B
    Mol Cancer; 2010 Jun; 9():147. PubMed ID: 20550649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12.
    Roubalová E; Kvardová V; Hrstka R; Borilová S; Michalová E; Dubská L; Müller P; Sova P; Vojtesek B
    Invest New Drugs; 2010 Aug; 28(4):445-53. PubMed ID: 19499188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.